GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US Neurosurgical Holding Inc (OTCPK:USNU) » Definitions » Cash Conversion Cycle

US Neurosurgical Holding (US Neurosurgical Holding) Cash Conversion Cycle : 0.00 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is US Neurosurgical Holding Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

US Neurosurgical Holding's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.
US Neurosurgical Holding's Days Inventory for the three months ended in Mar. 2024 was 0.
US Neurosurgical Holding's Days Payable for the three months ended in Mar. 2024 was 0.
Therefore, US Neurosurgical Holding's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 0.00.


US Neurosurgical Holding Cash Conversion Cycle Historical Data

The historical data trend for US Neurosurgical Holding's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Neurosurgical Holding Cash Conversion Cycle Chart

US Neurosurgical Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -211.26 -174.47 -600.36 - -

US Neurosurgical Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of US Neurosurgical Holding's Cash Conversion Cycle

For the Medical Care Facilities subindustry, US Neurosurgical Holding's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Neurosurgical Holding's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, US Neurosurgical Holding's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where US Neurosurgical Holding's Cash Conversion Cycle falls into.



US Neurosurgical Holding Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

US Neurosurgical Holding's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

US Neurosurgical Holding's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US Neurosurgical Holding  (OTCPK:USNU) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


US Neurosurgical Holding Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of US Neurosurgical Holding's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


US Neurosurgical Holding (US Neurosurgical Holding) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 325, Rockville, MD, USA, 20850
US Neurosurgical Holding Inc operates as a holding company in United State. It is a medical services company that partners with hospitals and physicians to operate facilities utilizing artistic and inventive technologies in medical treatment and diagnosis. It is engaged in providing medical treatment and diagnosis services that include stereotactic radiosurgery centers, utilizing gamma knife technology, and holds interests in radiological treatment facilities. The company is focusing on establishing cancer centers using intensity-modulated radiation therapy. Its gamma knife is a stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery.
Executives
Lawrence William St director 23 ASHLAND STREET, NEWBURYPORT MA 01950-1905
William F. Leimkuhler director 43 SALEM STRAITS RD, DARIEN CT 06820
Merriman Charles H Iii director
Alan Gold director, 10 percent owner, officer: President & Chairman 2400 RESEARCH BLVD, SUITE 325, ROCKVILLE MD 20850
Stanley S Shuman 10 percent owner C/O RIPPLEWOOD HOLDINGS LLC, ONE ROCKERFELLER PLAZA, NEW YORK NY 10020
Allen & Co Inc 10 percent owner 711 FIFTH AVENUE, NEW YORK NY 10022

US Neurosurgical Holding (US Neurosurgical Holding) Headlines

No Headlines